SomnoMed Limited (ASX:SOM)

Market Cap	169.64M
Revenue (ttm)	100.25M
Net Income (ttm)	-6.00M
Shares Out	216.11M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	228.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,070
Average Volume	68,279
Open	0.8000
Previous Close	0.7750
Day's Range	0.7850 - 0.8000
52-Week Range	0.2400 - 0.8500
Beta	0.99
RSI	66.53
Earnings Date	Aug 22, 2025

About Regulus Therapeutics

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SOM

Financial Performance

In 2024, SomnoMed's revenue was 91.65 million, an increase of 9.61% compared to the previous year's 83.62 million. Losses were -12.24 million, 53.0% more than in 2023.